Comment on Mulukutla et al. Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of “A+” Subtypes of Ketosis-Prone Diabetes. Diabetes Care 2018;41:2637–2640

Effects of Canagliflozin on Heart Failure Outcomes With and Without Preserved Ejection Fraction in Type 2 Diabetes: Results From the Canvas Program

“…◾ Patients with type 2 diabetes mellitus (T2DM) have an elevated risk of heart failure (HF), which may be caused by macrovascular disease, microvascular disease, volume overload, impaired kidney function, and/or direct adverse effects of diabetes on the myocardium [1][2][3][4][5][6] ◾ Sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of HF events in large scale trials [7][8][9][10][11] ; however, the mechanism of protection is unknown, and it is not known whether these benefits extend to patients with reduced and preserved ejection fraction (EF)…”

Response to Comment on Mulukutla et al. Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of “A+” Subtypes of Ketosis-Prone Diabetes. Diabetes Care 2018;41:2637–2640

“…We thank Dr. Heneberg ( 1 ) for the comments regarding our article ( 2 ) describing autoantibody responses to the IA-2 extracellular domain in ketosis-prone diabetes (KPD).…”